文献速递核素与放射性配体治疗

靶向α治疗的临床转化:演进还是革命?

Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
PubMed 文献 · J Nucl Med · 2023-04-13

本文综述靶向α治疗临床转化的重要研究,涵盖首个获美国食品药品监督管理局批准的α疗法223Ra-二氯化物治疗去势抵抗性前列腺癌骨转移,以及靶向α肽受体放疗和225Ac-PSMA-617治疗前列腺癌等。靶向α治疗是新型靶向癌症治疗中最有前景的领域之一,神经内分泌肿瘤和转移性前列腺癌的多项早期和晚期临床试验正在进行中。

要点

  • 223Ra-二氯化物是首个获美国食品药品监督管理局批准的α疗法,用于治疗去势抵抗性前列腺癌骨转移。
  • 靶向α肽受体放疗和225Ac-PSMA-617是前列腺癌治疗中临床转化的代表性概念。
  • 神经内分泌肿瘤和转移性前列腺癌的多项早期和晚期临床试验正在进行中。

核心结论

  • 靶向α治疗是新型靶向癌症治疗中最有前景的领域之一。
  • 这些研究将帮助理解靶向α治疗的短期和长期毒性,并可能确定合适的治疗联合搭档。

研究设计与样本

  • 本文为综述,总结从首个获美国食品药品监督管理局批准的α疗法223Ra-二氯化物起的重要研究。

主要发现

  • 223Ra-二氯化物获美国食品药品监督管理局批准用于治疗去势抵抗性前列腺癌骨转移。
  • 靶向α肽受体放疗和225Ac-PSMA-617用于治疗前列腺癌的临床转化概念已被纳入综述。
  • 综述涵盖评估新靶点的创新治疗模型和联合治疗。
  • 神经内分泌肿瘤和转移性前列腺癌的若干早期和晚期临床试验正在进行中。
  • 对额外早期研究有显著兴趣和投资。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The field of radioligand therapy has advanced greatly in recent years, driven largely by β-emitting therapies targeting somatostatin receptor-expressing tumors and the prostate-specific membrane antigen. Now, more clinical trials are under way to evaluate α-emitting targeted therapies as potential next-generation theranostics with even higher efficacy due to their high linear energy and short range in human tissues. In this review, we summarize the important studies ranging from the first Food and Drug Administration-approved α-therapy, 223Ra-dichloride, for treatment of bone metastases in castration-resistant prostate cancer, including concepts in clinical translation such as targeted α-peptide receptor radiotherapy and 225Ac-PSMA-617 for treatment of prostate cancer, innovative therapeutic models evaluating new targets, and combination therapies. Targeted α-therapy is one of the most promising fields in novel targeted cancer therapy, with several early- and late-stage clinical trials for neuroendocrine tumors and metastatic prostate cancer already in progress, along with significant interest and investment in additional early-phase studies. Together, these studies will help us understand the short- and long-term toxicity of targeted α-therapy and potentially identify suitable therapeutic combination partners.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Feuerecker B, Kratochwil C, Ahmadzadehfar H, et al. Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution? J Nucl Med. 2023. PMID: 37055224. doi:10.2967/jnumed.122.265353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。